Whether it provides lasting protection remains to be seen by Katherine Kahn, Staff Writer, MedPage Today December 13, 2023A computer rendering of RSV viruses in the lungs. Moderna’s mRNA-based RSV vaccine was effective at preventing RSV-associated lower respiratory tract disease in adults ages 60 and older, according to results of the randomized ConquerRSVopens in a...
by American College of Rheumatology Credit: CC0 Public Domain New research at ACR Convergence 2023, the American College of Rheumatology’s annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines. Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease marked by...
by Cleveland Clinic B-COBRA HA antigens for the vaccination and infection of pre-immune ferrets. Credit: Scientific Reports (2023). DOI: 10.1038/s41598-023-43003-2 Recent preclinical results indicate novel next-generation vaccine candidates developed at Cleveland Clinic protect against multiple strains of influenza and last longer than vaccines currently in use. The vaccines are part of Cleveland Clinic’s global vaccine research...
OCTOBER 18TH, 2023POSTED BY SARAH AVERY-DUKE DUKE UNIVERSITY“This study demonstrates proof-of-concept that a single vaccine that protects against both MERS and SARS viruses is an achievable goal,” Kevin Saunders says. “Given that one MERS and two SARS viruses have infected humans in the last two decades, the development of universal coronavirus vaccines is a global...
Studies in mice confirm that a vaccine candidate could target SARS and MERS Peer-Reviewed Publication DUKE UNIVERSITY MEDICAL CENTER URHAM, N.C. – A vaccine designed to protect against three different deadly coronaviruses shows success in mouse studies, demonstrating the viability of a pan-coronavirus vaccine developed by researchers at the Duke Human Vaccine Institute. Publishing in...
09 August 2023 By DAVID NIELD The vaccine counters the virus and stops it evolving. (QIMR Berghofer Medical Research Institute) Researchers have made a significant breakthrough in the development of the first-ever vaccine for the Epstein-Barr virus (EBV), a virus that causes infectious mononucleosis (IM, or ‘mono’) – also known as glandular fever. The virus can infamously lead to further health issues like cancer and multiple sclerosis (MS)....
by Bob Yirka, Medical Xpress Magnitude of ChulaCov-induced CD4+ and CD8+ T-cell responses. PBMCs were obtained on day 29 after the first dose from participants in each cohort (adult n = 11 per dose, elderly n = 12 per dose). The numbers above the bars show the GMT in the group. Error bars indicate 95% confidence intervals. a, SARS-Cov-2...
by Michael McCarthy., University of Washington Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health An experimental vaccine against breast cancer safely generated a strong immune response to a key...
by LAURAN NEERGAARD A man receives a flu shot in Brattleboro, Vt., on Tuesday, Oct. 26, 2021. Doctors have a message for vaccine-weary Americans: Don’t skip your flu shot this fall 2022. And for the first time, seniors are urged to get a special extra-strength kind. Credit: Kristopher Radder/The Brattleboro Reformer via AP, File Doctors...
by Ludwig Cancer Research Credit: CC0 Public Domain The cells of a subset of myeloproliferative neoplasms (MPNs), slow-growing blood cancers, have frameshift mutations in their calreticulin (CALR) gene that are associated with the disease. The tail end of this gene’s mutated protein product (CALRMUT) should be an ideal neoantigen. Yet T cells directed against the CALRMUT fragment...
